Correspondence Regarding Lee et al.: Placebo Control is Vital in Assessing Therapy in Chronic Cough
- PMID: 38955862
- DOI: 10.1007/s00408-024-00726-x
Correspondence Regarding Lee et al.: Placebo Control is Vital in Assessing Therapy in Chronic Cough
Comment in
-
Authors' Reply to Zhang and Morice on Inhaled Steroids in Chronic Cough.Lung. 2024 Aug;202(4):485-486. doi: 10.1007/s00408-024-00722-1. Lung. 2024. PMID: 38958716 No abstract available.
Comment on
-
Cough Response to High-Dose Inhaled Corticosteroids in Patients with Chronic Cough and Fractional Exhaled Nitric Oxide Levels ≥ 25 ppb: A Prospective Study.Lung. 2024 Jun;202(3):275-280. doi: 10.1007/s00408-024-00698-y. Epub 2024 May 11. Lung. 2024. PMID: 38733542
References
-
- Lee JH, Kang SY, Yu I, Park KE, Oh JY, Lee JH, Park SY, Kim MH, Jo EJ, Moon JY et al (2024) Cough response to high-dose inhaled corticosteroids in patients with chronic cough and fractional exhaled nitric oxide levels ≥ 25 ppb: a prospective study. Lung 202(3):275–280. https://doi.org/10.1007/s00408-024-00698-y - DOI - PubMed
-
- Mengru Z, Alyn HM (2024) Decoding the impact of the placebo response in clinical trials for chronic cough. ERJ Open (In press)
-
- McGarvey LP, Birring SS, Morice AH, Dicpinigaitis PV, Pavord ID, Schelfhout J, Nguyen AM, Li Q, Tzontcheva A, Iskold B et al (2022) Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials. The Lancet 399(10328):909–923. https://doi.org/10.1016/S0140-6736(21)02348-5 - DOI
-
- November 17, 2023 Meeting of the Pulmonary-Allergy Drugs Advisory Committee [ https://www.fda.gov/media/176353/download ]
-
- McGarvey L (2024) Inhaled corticosteroids for chronic cough: yes or FeNO? Lung. https://doi.org/10.1007/s00408-024-00705-2 - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
